Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation
March 18, 2026 |
Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
Lucid’s US Medical Affairs division unveils new proprietary insights tools to expand advisory capabilities.
LONDON & PHILADELPHIA, March 18, 2026 – Lucid Group, a global leader in healthcare communications and commercialisation, today announced that Rod MacKenzie, CMG, PhD, former Executive Vice President and Chief Development Officer at Pfizer, has been appointed as the new Chair of the Lucid Group Board of Directors. Dr MacKenzie will succeed Andy Black, who retired from the Board following the end of his term.
This appointment reflects a shared mission with Lucid Group to transform lives by ensuring innovative medicine doesn’t stop at approval but reaches the patients who need it most. His leadership marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
“Dr MacKenzie’s career is defined by his dedication to patient outcomes and a deep understanding that breakthrough science only matters when translated into action,” said Rick Sannem, CEO of Lucid Group. “His arrival supports our shared vision that we don’t just help clients talk about their science, we uncover the defining insights that shape behaviour so life-changing medicines find their rightful place in the market.”
Dr MacKenzie spent 34 years at Pfizer, where he led the Global Product Development division and oversaw 6,000 professionals dedicated to advancing innovative medicines and vaccines. He played a critical role in the development of both the Pfizer-BioNTech COVID-19 vaccine and antiviral, Paxlovid, in addition to serving on Pfizer’s Executive Leadership Team from 2016 to 2022. In recognition of his contributions to public health during the pandemic, he was appointed Companion of the Order of St Michael and St George by Queen Elizabeth II in 2022.
“Inventing and developing innovative medicines takes great science and execution. But translating that science into improved patient outcomes in clinical practice requires real strategic discipline,” said Dr MacKenzie. “Even brilliant science can struggle to break through, so innovative companies need a strategic partner like Lucid, whose integrated approach to solving complex challenges delivers changes in behaviours that successfully overcome treatment barriers. Lucid’s cre
ativity and unique data synthesis capabilities really stand out in the marketplace. I am thrilled to join the Lucid Board and share Lucid’s deep commitment to transforming lives across the globe.”
In addition to Dr MacKenzie’s appointment, Lucid’s US Medical Affairs division is unveiling new proprietary insights tools to expand its advisory capabilities at the Medical Affairs Professional Society (MAPS) conference in Denver from 22-25 March:
- Influence Amplifier™ – Closes the gap between communication and behaviour change by combining real-time behavioural insights, precision targeting, and adaptive analytics to expand peer-to-peer communication relevance and audience priorities.
- Impact Validator™ – Pinpoints precisely where efforts drive change through a five-step framework spanning clinical gaps and audience priorities, tailored interventions, omnichannel engagement, performance data, and adaptive refinement.
Together, these tools magnify and document scientific impact while delivering Precision Engagement™, a repeatable, self‑optimising cycle that continuously strengthens scientific influence, impact, and patient outcomes over time.
To demonstrate how Lucid Medical is enabling Medical Affairs teams to be strategic catalysts for change, it is offering free, 30-minute Impact Calibration™ sessions designed to map Medical Affairs teams’ current influence and spotlight opportunities for measurable growth.
About Lucid Group
Lucid Group, a global leader in healthcare communications and commercialisation, is driven by a mission to transform lives by bridging the gap between scientific discovery and patient impact. For life sciences organisations navigating their highest-stakes decisions, Lucid doesn’t just communicate science but ensures clients leave a lasting impact on the market and the patients they serve. Lucid brings together experts across Strategy Consulting, Scientific and Medical Communications, and Commercial Communications, fusing scientific rigour, strategic foresight, commercial ingenuity, creative storytelling, and deep human insight into an integrated force, powered by real-world evidence. This unique approach allows Lucid to uncover the ‘Lucid Truth’— the deep-seated insight that governs stakeholder behaviour and anchors bold, behaviour-changing ideas, executed at key moments and accelerated by AI and technology. To learn more about Lucid Group, visit www.wearelucidgroup.com and LinkedIn.
Media Contacts:
Chris Dougherty
CDougherty@reboundb2b.com
Elyse Cole
media@wearelucidgroup.com
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
Lucid affirms their commitment to staff development with new central services and HR hires
Lucid has recently appointed two new senior hires to their HR and central services team. Albert Capes joins as the Head of Facilities, bringing with him 11 years’ management experience...
Another spellbinding result for Lucid Group at the 2018 PMEAs
Lucid’s pioneering approach to medical education was clear to see as they scooped two top awards and a high commendation at last night’s awards ceremony.The first award was gained in...
A hat-trick of ten-year work anniversaries for Lucid Group
Lucid Group has been marking another landmark anniversary this month, with Michelle Sweet celebrating her ten-year service in style.Michelle is the third person this year to celebrate ten years at...
Promoting emotional health and wellbeing #LucidLife
For high achievers, maintaining a healthy equilibrium between mind, body and soul can be difficult. This is why Lucid have launched a comprehensive health and wellbeing programme aimed at equipping...
LUCID GROUP GET INTO THE HALLOWEEN SPIRIT WITH A SPOOKTACULAR BAKE-OFF
Lucid Group combined two of the most thrilling things of the year – Halloween and The Great British Bake Off final, to raise money for its charity partner, Wycombe Homeless...
LUCID GROUP WELCOMES NEW TALENT TO THEIR MEDICAL WRITING AND ACCOUNT TEAMS
Lucid’s commitment to finding the best talent has been confirmed with three new hires across different locations. Rachel Lafbery joins Lucid Partners as an Account Manager. Having worked in medical...
Lucid Group continues their expansion into the north west of England with new premises
Lucid Group continues their expansion into the north west of England with new premisesMacclesfield has long been a regarded as a key hub for scientific research, development and manufacturing in...
Lucid Group are shortlisted in three different categories at this year’s PMEA programme
Lucid’s talent for working together with their clients to create magical programmes is clear to see as they celebrate three of their campaigns making the 2018 PMEA finals, well as...
The Magic of Mindfulness
In support of World Mental Health Day, Lucid has been taking some time out for some mindful meditation and yoga. As Dr Amit Ray said, “Yoga means addition – addition...